Stock fact sheet · data as of
Lakefront Biotherapeutics N.V. (LKFT): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · Belgium · ADR · High Growth
Is LKFT undervalued?
LKFT has a margin of safety of 87%: the stock closed at 29.93 on 16 Oct 2026 against a GLS average fair value of 237.87. 6 of the 6 valuation models that produced a number sit above the price. Our screens treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
There is a wide gap between DCF (46.77) and GLS Growth (510.93). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
The nightly engine files LKFT under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.
Nine valuation models for LKFT
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 46.77 | +56% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | 90.77 | +203% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 477.38 | +1495% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 208.65 | +597% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 510.93 | +1607% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 92.73 | +210% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 44.42 | +48% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 35.50 | +19% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Lakefront Biotherapeutics N.V. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 7.5/10 puts LKFT among the more durable businesses we track: over ten years the metrics the score watches (revenue, EPS, book value, margins, cash flow, ROIC) have mostly moved the right way, year after year.
Returns on capital are moderate - ROIC 9.9%, ROE 9.9%, ROA 9.4% - with debt at 0.00 times equity and negative free cash flow.
Lakefront Biotherapeutics N.V. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 5/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | 9.9% |
|---|---|---|---|
| GLS Moat | 7.5 / 10 | ROE | 9.9% |
| Debt / equity | 0.00 | ROA | 9.4% |
| Free-cash-flow yield | -17.3% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 79: Good
With a Wheel Score of 79 - the Good band - Lakefront Biotherapeutics N.V. clears the Sunday Scan's "70 or higher" rule. The parts: Value 25/25, Health 11/20, Moat 11/15, Premium 20/20, Stability 11/20; Health (11/20) scores lowest.
Implied volatility is 54% on the near-the-money contracts 20-60 days out - inside the 35-60% range the Wheel Score pays full marks for: enough premium to be worth selling, not so much that the risk is unpaid. Chain open interest is thin - 149 contracts across every expiry - so fills at a fair price are not guaranteed; a 30-45-day put may not exist at a usable strike.
Volume runs at 227k shares a day on a market cap of $2.0B, with a beta of 0.12 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 11 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 87% margin of safety | |
| Health | 11 / 20 | Piotroski 5/9 | |
| Moat | 11 / 15 | moat 7.5/10 | |
| Premium | 20 / 20 | implied volatility 54% | |
| Stability | 11 / 20 | 227k shares/day, $2.0B cap, beta 0.12 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 11 Nov 2026, 26 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Lakefront Biotherapeutics N.V. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals, Inc. | 32.32 | 3.68 | -778% | 36Weak | $1.9B |
| VERA Vera Therapeutics, Inc. | 26.74 | 4.05 | -560% | 37Weak | $1.9B |
| RXRX Recursion Pharmaceuticals, Inc. | 3.74 | - | - | 45Weak | $2.0B |
| MRVI Maravai LifeSciences Holdings, Inc. | 7.07 | 2.40 | -195% | 31Weak | $2.0B |
| MLYS Mineralys Therapeutics, Inc. | 21.64 | 2.53 | -756% | 40Weak | $1.9B |
| ALMR Alamar Biosciences, Inc. | 27.42 | 20.52 | -34% | 20No options | $1.9B |
| BCRX BioCryst Pharmaceuticals, Inc. | 8.02 | 28.41 | +72% | 45Weak | $2.0B |
| IMNM Immunome, Inc. | 17.40 | 7.38 | -136% | 33Weak | $2.1B |
| VCEL Vericel Corporation | 40.25 | 20.44 | -97% | 54Fair | $2.1B |
| VRDN Viridian Therapeutics, Inc. | 18.38 | - | - | 45Weak | $2.1B |
| PHVS Pharvaris N.V. | 30.02 | 5.50 | -445% | 37Weak | $2.1B |
| NVAX Novavax, Inc. | 12.82 | - | - | 44Weak | $2.1B |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about LKFT
Is LKFT undervalued right now?
By the GLS models, yes: at 29.93 the stock is 87% below the average fair value of 237.87 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of LKFT and what does it mean?
LKFT scores 79 out of 100 (Good). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for LKFT?
237.87 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Lakefront Biotherapeutics N.V. report earnings next?
The next earnings report is due on 11 Nov 2026, 26 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does LKFT have listed options, and how liquid are they?
Yes. The nightly snapshot found 100 listed contracts with 149 open interest across all expiries and implied volatility of 54% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.